Diederik M Somford

List of Publications by Year
in descending order

68	3,326	279798	144013
papers	citations	23 h-index	57 g-index

80	80	80	3748
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. Radiology, 2011, 261, 46-66.	7.3	618
2	Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. Radiology, 2011, 259, 453-461.	7.3	537
3	Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen. Journal of Urology, 2010, 183, 520-528.	0.4	344
4	Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?. European Urology, 2017, 71, 517-531.	1.9	326
5	The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. European Urology, 2019, 75, 582-590.	1.9	188
6	The Predictive Value of Endorectal 3 Tesla Multiparametric Magnetic Resonance Imaging for Extraprostatic Extension in Patients with Low, Intermediate and High Risk Prostate Cancer. Journal of Urology, 2013, 190, 1728-1734.	0.4	177
7	Influence of Arterial Input Function on Hypoperfusion Volumes Measured With Perfusion-Weighted Imaging. Stroke, 2004, 35, 94-98.	2.0	103
8	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonanceâ€“Guided Biopsy for Early Risk Restratification in Active Surveillance of Low-Risk Prostate Cancer. Investigative Radiology, 2014, 49, 165-172.	6.2	83
9	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clinical Pharmacokinetics, 2016, 55, 1369-1380.	3.5	74
10	Diffusion and Perfusion MR Imaging of the Prostate. Magnetic Resonance Imaging Clinics of North America, 2008, 16, 685-695.	1.1	73
11	Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score â‰¥3 + 3 = 6 Upon Schematic TRUS-Guided Biopsy. Investigative Radiology, 2012, 47, 153-158.	6.2	65
12	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. Investigative Radiology, 2013, 48, 152-157.	6.2	63
13	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clinical Cancer Research, 2021, 27, 3595-3601.	7.0	53
14	Incidence and Risk Factors of Postoperative Urinary Retention and Bladder Catheterization in Patients Undergoing Fast-Track Total Joint Arthroplasty: A Prospective Observational Study on 371 Patients. Journal of Arthroplasty, 2018, 33, 1546-1551.	3.1	46
15	Complications and Adverse Events of Three Magnetic Resonance Imagingâ€“based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. European Urology Oncology, 2019, 2, 617-624.	5.4	46
16	Proximal and Distal Hyperattenuating Middle Cerebral Artery Signs at CT: Different Prognostic Implications. Radiology, 2002, 223, 667-671.	7.3	45
17	Drugâ€“drug interaction potential in men treated with enzalutamide: Mind the gap. British Journal of Clinical Pharmacology, 2018, 84, 122-129.	2.4	41
18	Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?. European Urology Oncology, 2020, 3, 216-223.	5.4	35

#	Article	IF	Citations
19	External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. European Urology Oncology, 2018, 1, 411-417.	5.4	31
20	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. European Urology Oncology, 2020, 3, 231-238.	5.4	30
21	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	3.2	25
22	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 2020, 16, 1371-1384.	2.4	25
23	Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer. Theranostics, 2021, 11, 1527-1541.	10.0	25
24	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imagingâ€“guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. European Urology Focus, 2019, 5, 407-415.	3.1	23
25	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e17-735.e25.	1.6	19
26	Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. World Journal of Urology, 2012, 30, 105-110.	2.2	18
27	Association of early CT abnormalities, infarct size, and apparent diffusion coefficient reduction in acute ischemic stroke. American Journal of Neuroradiology, 2004, 25, 933-8.	2.4	16
28	Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer and Prostatic Diseases, 2022, 25, 65-70.	3.9	12
29	The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications. Journal of Urology, 2022, 208, 109-118.	0.4	12
30	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castrationâ€“Resistant Prostate Cancer. Therapeutic Drug Monitoring, 2018, 40, 222-229.	2.0	11
31	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World Journal of Urology, 2015, 33, 1411-1417.	2.2	10
32	What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study. Prostate Cancer and Prostatic Diseases, 2021, 24, 1048-1054.	3.9	10
33	Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ESMO Open, 2022, 7, 100416.	4.5	10
34	Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology, 2022, 18, 2599-2614.	2.4	10
35	An Ex Vivo Phantom Validation Study of an MRI-Transrectal Ultrasound Fusion Device for Targeted Prostate Biopsy. Journal of Endourology, 2016, 30, 685-691.	2.1	9
36	Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy. Health Informatics Journal, 2020, 26, 1194-1207.	2.1	9

#	Article	IF	Citations
37	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castrationâ€resistant prostate cancer undergoing firstâ€line abiraterone acetate and prednisone treatment. Molecular Oncology, 2021, 15, 2453-2465.	4.6	9
38	Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi). European Urology Open Science, 2021, 28, 52-61.	0.4	9
39	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. Prostate Cancer and Prostatic Diseases, 2021, 24, 871-879.	3.9	8
40	Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative. Journal of Cancer Education, 2020, 35, 1141-1148.	1.3	7
41	Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands. BMC Urology, 2020, 20, 24.	1.4	7
42	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Oncology, 2021, 4, 618-627.	5.4	6
43	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 667658.	2.8	6
44	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 6279.	3.7	5
45	Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer. BJU International, 2021, 128, 46-56.	2.5	4
46	Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative. European Urology Open Science, 2021, 26, 18-26.	0.4	4
47	Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 60.e1-60.e1.	1.6	4
48	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. Journal of Palliative Medicine, 2021, 24, 1789-1797.	1.1	4
49	Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer. Nuclear Medicine Communications, 2021, 42, 476-481.	1.1	3
50	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. Clinical Genitourinary Cancer, 2022, 20, 43-52.	1.9	3
51	VALUE OF 3 TESLA MULTI-MODALITY DIRECTED MR GUIDED BIOPSY TO DETECT PROSTATE CANCER IN PATIENTS AFTER AT LEAST TWO PREVIOUS NEGATIVE BIOPSIES AND ELEVATED PSA. Journal of Urology, 2009, 181, 706.	0.4	2
52	Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection. World Journal of Urology, 2014, 32, 461-467.	2.2	2
53	Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 4523-4523.	1.6	2
54	Reassessment of Prostate Biopsy Specimens for Patients Referred for Robot-assisted Radical Prostatectomy Rarely Influences Surgical Planning. European Urology Open Science, 2021, 28, 36-42.	0.4	2

#	Article	IF	Citations
55	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. Journal of Personalized Medicine, 2022, 12, 726.	2.5	2
56	298 VALUE OF 3 TESLA MULTIMO DALITY MR GUIDED BIOPSY (MRGB) TO DETECT PROSTATE CANCER IN PATIENTS AFTER AT LEAST TWO PREVIOUS NEGATIVE BIOPSIES AND AN ELEVATED PSA. European Urology Supplements, 2009, 8, 195.	0.1	1
57	828 INTRAPROSTATIC LOCATION OF PROSTATE CANCER IN PATIENTS WITH > 2 NEGATIVE PROSTATE BIOPSY SESSIONS AND AN ELEVATED PSA USING MR GUIDED BIOPSY FOR TUMOUR DETECTION AND LOCATION VALIDATION. European Urology Supplements, 2009, 8, 327.	0.1	1
58	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2021, 7, 788-796.	3.1	1
59	Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 72.e7-72.e14.	1.6	1
60	Re: Markus Graefen, Thorsten Schlomm. Active Surveillance for Low-risk Prostate Cancer: Some Questions Are Answered, but Many Questions Remain. Eur Urol 2013;63:604â€“5. European Urology, 2013, 64, e65-e66.	1.9	0
61	Editorial Comment. Journal of Urology, 2013, 190, 873-873.	0.4	0
62	799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. Annals of Oncology, 2020, 31, S606.	1.2	0
63	PD61-02â€ƒPREOPERATIVE PSMA PET/CT AS A PREDICTOR OF BIOCHEMICAL PERSISTENCE AND EARLY BIOCHEMICAL RECURRENCE. Journal of Urology, 2021, 206, .	0.4	0
64	Patientsâ€™ perspective on the quality of prostate cancer follow-up care.. Journal of Clinical Oncology, 2021, 39, 175-175.	1.6	0
65	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. Journal of Clinical Oncology, 2012, 30, 105-105.	1.6	0
66	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
67	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. Drugs - Real World Outcomes, 2022, , 1.	1.6	0
68	Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands. World Journal of Urology, 2022, , 1.	2.2	0